Venous thromboembolism (VTE) continues to be a common medical problem requiring the need for rapid treatment with anticoagulant therapy. Until the recent availability of the direct oral anticoagulants for treatment of VTE, the option for oral anticoagulation was limited to warfarin therapy. The addition of these new medications has been welcomed, but has led to added complexities in deciding the most appropriate agent for each patient based on individual risk factors. Furthermore, there are several circumstances where optimal duration of therapy is not well established. This article will focus on the diagnosis of VTE, the choice of anticoagulant and treatment duration.
Introduction
Venous thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary embolism (PE), causes significant morbidity and mortality, as well as a substantial burden on the health system in Australia. In 2008, there were approximately 15 000 new cases of VTE, with a cost of nearly 2 billion dollars to the health system. 1 Currently, in Australia, there are no national guidelines for the prevention or treatment of VTE. Worldwide, there are many guidelines that describe the preferred treatment of VTE, including those by the American College of Chest Physicians (ACCP) 2 and the National Institute for Health and Care Excellence (NICE) 3 in the United Kingdom. Each publication differs in its recommendations.
Over the past 5 years, there have been substantial changes in the available treatment options for VTE. The direct oral anticoagulants (DOAC), including the direct thrombin inhibitor, dabigatran and the factor Xa inhibitors, rivaroxaban, apixaban and edoxaban, are efficacious and safe for treatment and prevention of VTE. [4] [5] [6] [7] [8] In Australia, rivaroxaban and apixaban are currently subsidised by the Pharmaceutical Benefits Scheme for the treatment of VTE. By contrast in New Zealand, until recently dabigatran has been the only subsidised drug for the same indication, but rivaroxaban has been approved from August 2018. This broadening of options has led to a paradigm shift in the way that VTE is treated, with many physicians prescribing DOAC rather than warfarin as first-line treatment given the predictable pharmacological properties of DOAC.
Diagnosis of VTE
The signs and symptoms of DVT and PE are non-specific, and as such it is important to establish the likelihood of either diagnosis using a clinical decision rule (CDR). Using these rules can aid in diagnosis but will also reduce unnecessary radiological tests and financial costs to the healthcare system.
There are many CDR that stratify patients with suspected VTE into risk categories, but the prospectively validated Wells score is most commonly used. [9] [10] [11] [12] [13] CDR cannot safely exclude VTE and thus imaging and D-dimer should be incorporated into a diagnostic pathway.
D-Dimer is a degradation product of cross-linked fibrin, which is highly sensitive but not specific for the diagnosis of acute VTE. D-Dimer is almost always elevated in acute VTE, but can be raised in many other conditions such as sepsis, malignancy, trauma, pregnancy or surgery.
effectively excludes the likelihood of DVT so that imaging is not required. On the other hand, D-dimer testing is not recommended in patients with a high likelihood of VTE as diagnostic imaging must be undertaken regardless of the D-dimer result.
Evaluation of suspected pulmonary embolism
An algorithm for suspected diagnosis of PE is shown in Figure 1 . 16 In all cases, the Wells score or simplified Wells score should be determined (Table 1) . The simplified Wells score is as effective as the original scoring system. 17 If PE is considered likely based on the CDR, computed tomography pulmonary angiography (CTPA) or ventilation-perfusion (V/Q) scan should be performed. CTPA has become the most widely used imaging modality for patients with suspected PE. A negative CTPA excludes PE and identifies alternative diagnoses. V/Q scan is suitable for patients with renal impairment as it does not require potentially nephrotoxic contrast. A negative V/Q scan similarly excludes PE, while a high probability finding is diagnostic. However, a sizeable proportion of V/Q scans are non-diagnostic and patients will require serial ultrasound (US) of the legs or CTPA to rule out PE. Elements to consider when choosing initial imaging are listed in Table 2 .
If PE is considered unlikely, the Pulmonary Embolism Rule-Out Criteria (PERC) should be applied. 18 Importantly, PERC applies to patients younger than 50 years of age where the estimated incidence of PE is low (<15%). The PERC has been prospectively validated to stratify patients into those who need a D-dimer performed to exclude PE and those who do not. 19 If all of the eight criteria are met, the likelihood of the patient having a PE is less than 2% (which is lower than the negative predictive value of a V/Q scan) and no further investigation for PE is necessary. 
Evaluation of suspected deep vein thrombosis
The Wells score for DVT ( Table 3) should be determined. An algorithm for suspected DVT is shown in Figure 2 . 20 Using a CDR in conjunction with a sensitive D-dimer assay can reduce the need for further imaging in up to 40% of patients with suspected DVT. 21 If DVT is considered likely based on the Wells score, then whole-leg US should be performed. 20 A single negative whole-leg US reliably excludes DVT, with the risk of VTE at 3-month follow-up being less than 1%. 22 If DVT is considered unlikely based on the Wells score, a D-dimer should be performed. If negative, DVT is effectively excluded. If the D-dimer is positive, US should be undertaken.
Anticoagulant options for acute VTE
Low-molecular-weight heparin (LMWH) bridging to warfarin has been the mainstay of treatment for VTE until recently. Following the diagnosis of VTE, established practice is to commence therapeutic LMWH with overlapping warfarin. Warfarin is monitored by the international normalised ratio (INR), and the dose should be adjusted for an INR of 2.0-3.0. LMWH should continue for a minimum of 5 days or longer until the INR has been greater than 2.0 for two consecutive days.
The availability of DOAC has simplified treatment of VTE due to predictable pharmacokinetics, with no need for regular monitoring, no known food interactions and fewer drug interactions. Apixaban and rivaroxaban do not require an initial period of parenteral anticoagulation, but by contrast dabigatran requires at least 5 days of therapeutic parenteral anticoagulation prior to its commencement. A summary of the differences between treatment options is shown in Table 4 .
Apixaban and rivaroxaban have been extensively evaluated in the treatment and prevention of VTE [5] [6] [7] 23 and are approved for use for these indications. Both medications are as efficacious as warfarin in preventing recurrent VTE. Compared with warfarin, rivaroxaban has similar rates of major and clinically relevant nonmajor bleeding (CRNMB), 7 whereas apixaban has lower rates of major bleeding including intracranial haemorrhage. 5 Both apixaban and rivaroxaban have a period of dose intensification during initial treatment (10 mg twice daily (BD) for 7 days and 15 mg BD for 21 days, respectively) before commencing a maintenance dose of 5 mg BD for apixaban and 20 mg daily for rivaroxaban. Given that the risk of recurrent thrombosis is highest in the acute period following VTE, it is important that the dose intensification period occurs as per the schedule. There are no acceptable dose modifications for age, weight or renal function when using apixaban or rivaroxaban for treatment of VTE.
Other oral anticoagulants have been shown to be effective in treatment of VTE but are yet to be available or subsidised in Australia. Dabigatran can be used for stroke prevention in atrial fibrillation and VTE prevention in orthopaedic surgery. It is as efficacious as warfarin for treatment of acute VTE with a similar safety profile. 4 Currently, it has been approved by the Therapeutic Goods Administration for VTE treatment but is not subsidised on the Pharmaceutical Benefits Scheme.
Edoxaban is another oral factor Xa inhibitor which has been evaluated in the treatment of acute VTE and has been shown to have similar efficacy and safety profile as warfarin. 8 It is also emerging as a treatment option for cancer-associated VTE. 24 Edoxaban is not available in Australia.
Anticoagulant choice for acute VTE
The authors support the ACCP's recommendations that DOAC be used in preference to warfarin given the similar efficacy and safety profiles with predictable pharmacokinetics and no need for regular monitoring. In Australia, this means that apixaban or rivaroxaban will 
Cancer-associated VTE
Patients with malignancy have a higher risk of VTE and treatment can often be difficult given the increased propensity for bleeding. 26 In patients with malignancy, LMWH is more effective than warfarin in preventing recurrent VTE with similar rates of bleeding, 27, 28 and thus LMWH is the standard of care in this patient group. There is emerging evidence that DOAC are effective in treating cancer-associated VTE. Edoxaban has been shown to be non-inferior to LMWH for recurrent VTE but is associated with an increase in major bleeding (6.9% vs 4.0%, P = 0.04) and in particular upper gastrointestinal bleeding. 25 A recent study compared rivaroxaban versus LMWH in this patient group and reported that the rate of recurrent VTE after 6 months of treatment was 4% and 11% in the rivaroxaban and LMWH groups, respectively (hazard ratio 0.43; 95% confidence interval 0.19-0.99). Rates of major bleeding were similar in both groups (4% vs 6% respectively). However, CRNMB occurred in 13% of patients in the rivaroxaban arm and only 4% in the LMWH arm (hazard ratio 3.76; 95% confidence interval 1.63-8.69).
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The efficacy and safety of DOAC in malignancy are not yet firmly established, and LMWH still remains the preferred therapeutic option. However, a DOAC may be considered in patients who find long-term parenteral therapy unacceptable.
Duration of anticoagulation for acute proximal DVT or PE
VTE can be considered in the following subgroups, which have been adapted from the International Society on Thrombosis and Haemostasis and ACCP: 2, 30 1 VTE provoked by a major surgery or trauma 2 VTE provoked by a minor transient risk factor
This includes minor surgery, hospital admissions for a medical illness, oestrogen therapy, pregnancy, leg injury or long-haul air travel 3 Unprovoked VTE or VTE associated with ongoing risk factors such as antiphospholipid syndrome 4 Cancer-associated VTE.
Symptomatic proximal DVT and PE VTE provoked by major surgery or trauma
The risk of recurrent VTE is low if provoked by major surgery (3% recurrence rate at 5 years). 31 Proximal DVT or PE that is provoked by a major transient risk factor can be treated with 3 months of anticoagulation, rather than a longer period of treatment unless there are persisting risk factors.
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VTE provoked by minor transient risk factors
The risk of recurrence following VTE provoked by a minor transient risk factor is intermediate (15% at 5 years). 31 ACCP guidelines suggest 3 months of anticoagulation over extended therapy. 2 However, the authors feel that due to clinical equipoise in this area, each patient should undergo individual assessment to determine treatment duration based on risk of recurrence if anticoagulation is stopped and risk of bleeding on extended anticoagulation, taking into consideration patient preference.
Unprovoked VTE
The risk of recurrent VTE following unprovoked events is up to 30% by 5 years. 2, 31 As such, the ACCP recommends indefinite anticoagulation for unprovoked events, and the National Institute for Health and Care Excellence guidelines recommend considering extension of therapy beyond 3 months, 2,3 especially among patients without an increased risk for bleeding. The risk of recurrence starts when anticoagulation is ceased regardless of the preceding duration of anticoagulation. 32 The authors agree that unprovoked VTE should be treated for at least 3 months, and many patients should be considered for indefinite anticoagulation.
Cancer-associated VTE
Initial treatment with LMWH should continue for at least 6 months. 3, 33 Following this, extended anticoagulation in the setting of active malignancy is generally recommended, 2, 33 but a dose reduction may be appropriate.
Anticoagulant choice for extended treatment of VTE
Many patients with unprovoked VTE will continue with indefinite anticoagulation and so an important decision lies in the most suitable agent for extended therapy.
The AMPLIFY-EXT study compared apixaban 2.5 mg BD, apixaban 5 mg BD and placebo for a 12-month period following an initial 6-12 months of therapeutic anticoagulation. The results showed that both doses of apixaban significantly reduced recurrent VTE (1.7% for apixaban 2.5 mg BD, 1.7% for apixaban 5 mg BD and 8.8% for placebo). Rates of major bleeding in both apixaban arms were comparable to placebo (0.2% for apixaban 2.5 mg BD, 0.1% for apixaban 5 mg BD and 0.5% for placebo). CRNMB occurred in 2.3% of patients receiving placebo as compared with 3.0% of patients receiving apixaban 2.5 mg BD and 4.2% receiving the 5 mg BD dose. 23 The EINSTEIN CHOICE study compared rivaroxaban 10 mg and rivaroxaban 20 mg with aspirin for extended anticoagulation following a 6-12-month period of therapeutic anticoagulation. Rivaroxaban 10 mg was as efficacious as rivaroxaban 20 mg in preventing recurrent VTE, and both doses of rivaroxaban were superior to aspirin, with recurrence rates of 1.5% for rivaroxaban 10 mg, 1.2% for rivaroxaban 20 mg and 4.4% for aspirin. There was no statistically significant difference in major bleeding or CRNMB between the treatment arms. 34 Apixaban and rivaroxaban are efficacious for extended treatment of VTE, with both medications showing similar rates of recurrence and bleeding at treatment and prophylactic doses. Although either dose could be used for patients on extended anticoagulation, the minimum dose with pharmacological benefit seems an attractive alternative. Rivaroxaban 10 mg currently does not have an indication for secondary prevention of VTE in Australia.
Although aspirin reduces risk of recurrent VTE 35, 36 its use has been supplanted by low-dose apixaban and rivaroxaban, which have lower rates of recurrent VTE and similar safety profiles. As such, aspirin is no longer offered as routine secondary prevention of VTE unless it is required for another indication.
Risk stratification for treatment cessation in unprovoked VTE
There are several risk stratification models that have been developed to ascertain risk of recurrence following an unprovoked VTE. These tools aim to identify patients who have a low risk of recurrent VTE and could potentially cease anticoagulation, and high-risk patients who would be more suitable to continue anticoagulation. These tools include the DASH score, 37 the HERDOO2 score 38, 39 and the Vienna Prediction Model 40, 41 and each contains several variables, including age, gender, site of VTE, D-dimer and weight.
A recent systematic review has found that all models required further external validation prior to use outside of the research setting, and are not ready for routine use in the general population. 42 
Special circumstances Massive PE
Massive PE is defined as acute PE associated with haemodynamic instability (sustained hypotension with systolic blood pressure <90 mmHg). In such patients with low risk of bleeding, systemic thrombolysis followed by therapeutic anticoagulation is appropriate. Systemic thrombolysis has been shown to restore more rapidly right ventricular function and pulmonary perfusion, 43 but at the expense of increased major bleeding and rates of intracranial haemorrhage of approximately 2%. 44, 45 The recent PEITHO study compared systemic thrombolysis plus heparin with placebo plus heparin in patients with submassive PE (right heart dysfunction but normotensive). The study demonstrated that systemic thrombolysis reduces rates of haemodynamic decompensation but with significantly increased rates of major bleeding compared with therapeutic anticoagulation alone (11.5% vs 2.4% respectively). 46 Thus, systemic thrombolysis is not recommended routinely in normotensive patients with acute PE and cardiac dysfunction but can be considered in those with very poor cardiorespiratory reserve and a low bleeding risk. 2, 45 Distal DVT Distal DVT is defined as DVT isolated to the infrapopliteal deep leg veins. It is thought to have lower rates of propagation to proximal DVT or PE, and lower rates of recurrence. 2, 47 Because the associated risks are lower, the absolute benefit of therapeutic anticoagulation is also unclear. Several options for treatment can be considered, including anticoagulation of differing intensities and duration, or surveillance with repeat imaging.
A meta-analysis in 2012 concluded that treatment with anticoagulation for distal DVT may decrease incidence of PE and propagation to proximal DVT, but the methodology in the reviewed studies was mostly of poor quality. 48 The Anticoagulant Therapy for Symptomatic Calf Deep Vein Thrombosis (CACTUS) trial evaluated outpatients with symptomatic distal DVT who received either 6 weeks of LMWH or placebo and found no difference in rates of extension to proximal DVT or PE but higher bleeding rates in the treatment group. However, the small sample size meant that the primary outcome of propagation to proximal VTE or PE was not statistically significant. 49 The ongoing Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis (TWISTER) study is a prospective cohort study that aims to evaluate the efficacy of therapeutic anticoagulation for 2 weeks (NCT01252420).
Based on the evidence to date, the authors agree with the ACCP guidelines that a patient with a symptomatic distal DVT should receive anticoagulation for 6-12 weeks. In patients with a high risk of bleeding, serial US (two US over 2 weeks) can be adopted.
Isolated subsegmental pulmonary embolism
The use of highly sensitive computed tomography has led to an increase in the diagnosis of isolated subsegmental pulmonary embolism. 50 However, the potential for false-positive interpretation and inter-observer variability remains high. 51 A recent Cochrane review has found that there was insufficient evidence to make conclusions with regards to treatment 52 and the outcomes of treatment have not been prospectively evaluated.
If a DVT or more proximal PE is identified on imaging, then anticoagulation should be initiated. Close monitoring without anticoagulant therapy can be considered if there is isolated subsegmental pulmonary embolism, particularly in patients with high risk of bleeding. If there are any risk factors for extension or recurrent VTE including hospitalisation, immobility or malignancy, then the patient should be anticoagulated.
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Pregnancy LMWH is the standard of care for pregnancy-associated VTE. The oral factor Xa inhibitors and the direct thrombin inhibitor, dabigatran, are contraindicated in pregnancy. Prior to commencing anticoagulation, women of childbearing age should be counselled about the need for vigilant contraception if being treated with a DOAC or warfarin, and to seek urgent medical contact if pregnancy is confirmed.
Thromobophilia testing
Thrombophilia (TP) is a hypercoagulable state, which increases VTE risk. Testing for inherited TP includes deficiencies in the natural anticoagulants protein S, protein C and antithrombin, as well as gain-of-function mutations including factor V Leiden (FVL) and prothrombin G20210A mutation (PGM). Antiphospholipid antibodies, including detection of a lupus anticoagulant, anticardiolipin or anti-beta-2 glycoprotein, are considered an acquired TP.
TPs can be considered strong or weak depending on their risk of VTE recurrence. Strong TP includes deficiencies in antithrombin, protein C or protein S, and homozygosity for FVL or PGM. These are rare but are associated with a stronger risk for recurrent VTE, especially among those with a family history. 54, 55 FVL and PGM heterozygosity, although more common (prevalence in the Caucasian population of 5% and 3%, respectively), are considered weak TP and generally do not influence the decision to prolong anticoagulation. 54, 55 Following a provoked VTE, the risk of recurrence is low and therefore TP testing is not recommended. [56] [57] [58] Testing may be considered after careful counselling in younger patients with an unprovoked VTE and a strong family history, particularly if cessation of anticoagulation is being considered.
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Reversal agents for DOAC Currently, there are no routinely available reversal agents for the factor Xa inhibitors. Andexanet alfa (andexanet) and ciraparantag are two agents in advanced clinical trials. [60] [61] [62] Idarucizumab is a monoclonal antibody that is effective in reversing the anticoagulant effect of dabigatran. 63 Reversal agents should only need to be used for lifethreatening bleeds and other emergency situations. A recent study reported that four-factor prothrombin complex concentrate partially reverses the anticoagulant effect of rivaroxaban but has no significant effect on bleeding duration, and tranexamic acid does not have any measurable effects. 64 As such, other options should be considered including drug discontinuation, supportive care and use of other haemostatic agents. For further management strategies with regards to management of DOAC-related bleeding, we refer to the previously published IMJ article. 65 
Conclusion
The availability of DOAC has transformed treatment recommendations for many patients diagnosed with VTE. These newer anticoagulants provide effective, safe and practical alternatives to warfarin, as well as offering attractive options for low-dose extended therapy. However, there is definitely still a place for warfarin use in certain patient groups and the most appropriate choice of anticoagulant should be assessed on an individualised Venous thromboembolism: an update basis. There are still many areas of VTE treatment where there is uncertainty with regards to optimal duration of therapy, and further prospective trials are needed to guide treatment.
